| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
ICI 89406 manufacturers
- ICI 89406
-
- $66.00
-
2026-07-15
- CAS:53671-71-9
- Purity: 99.92%
- Supply Ability: 10g
|
| | ICI 89406 Basic information |
| Product Name: | ICI 89406 | | Synonyms: | N-[2-[3-(2-CYANOPHENOXY)-2-HYDROXYPROPYLAMINO]ETHYL]-N'-PHENYLUREA;ICI 89406;C025716;Urea, N-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethyl)-N'-phenyl-;1-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-3-phenylurea;Adrenergic Receptor,Inhibitor,inhibit,ICI-89406,Beta Receptor,ICI 89406,ICI89406;ICI 89406, 10 mM in DMSO | | CAS: | 53671-71-9 | | MF: | C19H22N4O3 | | MW: | 354.4 | | EINECS: | | | Product Categories: | | | Mol File: | 53671-71-9.mol |  |
| | ICI 89406 Chemical Properties |
| Melting point | 155-156 °C(Solv: acetonitrile (75-05-8)) | | Boiling point | 575.0±50.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | Soluble in ethanol and to 100 mM in DMSO | | form | Powder | | pka | 12.29±0.46(Predicted) | | color | White to off-white |
| | ICI 89406 Usage And Synthesis |
| Uses | ICI 89406 is beta-1-selective antagonist. | | Definition | ChEBI: 1-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-3-phenylurea is a member of ureas. | | Biological Activity | β -adrenergic antagonist and low efficacy partial agonist; does not affect resting cardiac parameters. | | in vivo | | Animal Model: | Rats[2]. | | Dosage: | 0.6, 5 or 50 mg/kg. | | Administration: | Orally (5 or 50 mg/kg), i.p. (5 mg/kg), i.v. 0.6 (0.6 mg/kg) (Pharmacokinetic Analysis). | | Result: | Following oral administration, the dose of 5 mg/kg urinary and faecal excretion accounted for 5.8 + 0.7% and 96.4 + 2.1%. The dose of 50 mg/kg urinary and faecal excretion accounted for 14.0 + 4.0% and 78.4 + 2.4%. The proportions of unchanged drug and metabolites in urine were independent of the dose. The unchanged drug accounted for 81.6% of the faecal components after a dose of 5 mg/kg but this was reduced to 47.8%. |
|
| | ICI 89406 Preparation Products And Raw materials |
|